STOCK TITAN

Aadi Bioscience to Participate at the Jefferies “Biotech on the Bay” Summit

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Aadi Bioscience, a biopharmaceutical company focusing on precision therapies for genetically-defined cancers, will participate in the Jefferies 'Biotech on the Bay' Summit on April 26-27, 2022, in Miami, FL. CEO Neil Desai and the executive team will be available for one-on-one meetings. The company aims to provide transformational therapies for cancer patients with mTOR pathway alterations. Aadi's drug FYARRO received FDA approval in November 2021 and was commercially launched in February 2022, targeting advanced perivascular epithelioid cell tumors. Aadi has also initiated a registrational trial, PRECISION 1.

Positive
  • None.
Negative
  • None.

LOS ANGELES, April 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., and senior members of Aadi's executive team will participate at the Jefferies “Biotech on the Bay” Summit, to be held in-person in Miami, FL April 26-27, 2022.

The Aadi executive team will be available for one-on-one meetings throughout the conference. Please contact your sales representative at Jefferies to register for a meeting with the company.

About Aadi Bioscience

Aadi is a biopharmaceutical company focused on precision therapies for genetically-defined cancers. Aadi’s primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. In November 2021, Aadi received FDA approval for FYARRO™ for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), and in February 2022 Aadi announced the commercial launch of FYARRO in this indication. FYARRO is an mTOR inhibitor bound to human albumin that has demonstrated significantly higher tumor accumulation, greater mTOR target suppression, and increased tumor growth inhibition over other mTOR inhibitors in preclinical models.

Based on data from the AMPECT trial with FYARRO and following discussions with the FDA about other emerging data with FYARRO, Aadi has initiated PRECISION 1, a tumor-agnostic registrational trial in mTOR inhibitor-naïve solid tumors harboring TSC1 or TSC2 inactivating alterations. More information on Aadi’s development pipeline is available on the Aadi website at www.aadibio.com.

Contacts:

Investors

Irina Koffler
LifeSci Advisors LLC
ikoffler@lifesciadvisors.com

 


FAQ

What event will Aadi Bioscience participate in on April 26-27, 2022?

Aadi Bioscience will participate in the Jefferies 'Biotech on the Bay' Summit in Miami, FL.

Who from Aadi Bioscience will be present at the Jefferies Summit?

CEO Neil Desai and senior members of Aadi's executive team will represent the company.

What is the main focus of Aadi Bioscience?

Aadi Bioscience focuses on developing precision therapies for genetically-defined cancers with mTOR pathway gene alterations.

What is FYARRO and when was it approved by the FDA?

FYARRO is an mTOR inhibitor approved by the FDA in November 2021 for treating advanced perivascular epithelioid cell tumors.

What is the PRECISION 1 trial launched by Aadi Bioscience?

The PRECISION 1 trial is a registrational study for mTOR inhibitor-naïve solid tumors with TSC1 or TSC2 alterations.

Aadi Bioscience, Inc.

NASDAQ:AADI

AADI Rankings

AADI Latest News

AADI Stock Data

58.17M
22.17M
9.96%
49.17%
1.14%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PACIFIC PALISADES